Power
Reimagined

*Except for individuals with HIV RNA >500,000 copies/mL, hepatitis B virus (HBV) co-infection, or who will start antiretroviral therapy before results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available.

Read more »

Indication
DOVATO is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known substitutions associated with resistance to the individual components of DOVATO

DHHS=Department of Health and Human Services.

Not an actual patient.

Indication
DOVATO is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known substitutions associated with resistance to the individual components of DOVATO

Discover Dovato

GEMINI 1 & 2 TRIALS

See trial results and 96-week long-term data

SEE LONG-TERM DATA

Read more »

RESISTANCE RESULTS

Data available through 96 weeks in treatment-naïve adult patients with HIV-1

SEE 96-WEEK DATA

Read more »

RISKS & SIDE EFFECTS

Info about the possible risks and side effects, including drug-related adverse events and rates of discontinuation

LEARN MORE

Read more »

Models not actual patients

A deeper Look at DOVATO

EDUCATIONAL RESOURCES

Learn more about DOVATO with videos, guidelines, and an interactive quiz

Read more »

PATIENT SUPPORT

Get details on the patient support available for prescribed patients

Read more »

Reference: 1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. US Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Updated December 18, 2019. Accessed December 19, 2019.

DLLWCNT200002